Close Menu

NantHealth

A roundup of some of the precision oncology-focused research presented at the Gastrointestinal Cancer Symposium in San Francisco, Jan. 23 to 25.

Recent studies question the clinical utility of tumor mutational burden as a biomarker for immuno-oncology response, and the FDA clearance includes no therapeutic indications.

The approval of its Omics Core assay for tumor-normal mutational profiling opens the door for payor reimbursement, which is key to reaching profitability, NantHealth said.